Our studies till today, we have continued to clarify the PKC signal pathway, the results from these studies will guide our new projects. We found that EpCAM, Claudin and tetraspanin are the important proteins that have been found effective in the signaling pathway.
Following this project, studies on the effect of exosomes released from ovarian cancer cells by primary ovarian cancer cells and healthy epithelium and mesothelial cells by uptake of 1001 Tubitak Project and carcinogenesis mechanism in target cells are continuing.
According to the results obtained from these studies, it is aimed to improve the diagnosis and treatment of ovarian and colon cancer. In this context, synthesis of targeted therapeutic molecules, development of diagnostic kits optimized for diseases and cancer, and full characterization of synthesized molecules are studied.
The selective delivery of highly effective drugs by antibody drug conjugates (ADC) is a promising approach for the treatment of cancer to overcome the multidrug resistance (MDR). The monoclonal antibody (mAb), which has been highly expressed by specific cancer type, may be linked to payload which targets the DNA or microtubules using the site-specific conjugation methods to synthesize the ADC. Both the use of the target antibody and the use of a hydrophilic linker may help to overcome the MDR. In addition, we are planning to produce surface functionalized exosome (mAb-exosome, drug-exosome, peptide-exosome conjugates) loaded drug for specific targeting.
In this content, it is tried to find specific biomarkers for rare diseases and cancer. The biological nanovesicles, namely exosomes which include some specific proteins called “Exosome Markers”. The study aims to develop diagnostic kit based on exosome to help diagnose cancer types at an early stage and also determine the stage of the cancer by using statistical algorithms. The specific biomarker in the patient’s blood samples will be screened by using Exosome-mAb/Drug/Peptide Conjugation.
The group also work on characterization of biopharmaceutics. They should be carefully monitored and characterized to prove has no significant difference in the aspect of physicochemical properties and biological activities. Using state-of-the-art technology make possible to fully characterization of these products. Ultra-Performance Liquid Chromatography (UPLC) is used for total protein concentration (Protein A), size exclusion (SEC), ion exchange (IEX), hydrophobic interaction (HIC) analyses. Capillary Electrophoresis (CE) is used for purity, isoelectric point, acidic, basic variants and molecular weight determination (IgG Purity/Heterogeneity, cIEF, CZE, CE-SDS). Also, kinetic properties, Fab binding, FcRn binding, C1q binding analysis are done by Surface Plasmon Resonance (SPR).
The Scientific and Technological Research Council of Turkey (TUBITAK) - RD : Ovaryum Kanserinde Tetraspain-Claudin-Epcam Tümör Belirleyici Proteinlerinin ve Protein Kinaz C'nin Rolünün Belirlenmesi
The Scientific and Technological Research Council of Turkey (TUBITAK) - RD : Kanser ve Osteoporoz Tedavisi İçin Monoklonal Antikor Etkin Maddeli Biyobenzer İlaç Geliştirilmesi ve Üretilmesi
DEÜ BAP - Dokuz Eylul University Scientific Research Projects Coordination Unit - RD : Kolon Kanserinde Etkin Bazı Yolaklar Üzerine PKC İzoenzim Aktivitelerinin Etkisinin in vitro İncelenmesi
The Scientific and Technological Research Council of Turkey (TUBITAK) - RD : Ovaryum Kanser Hücrelerinden Salınan Eksozomların Primer Ovaryum Kanser Hücreleri İle Sağlıklı Epitel Ve Mezotel Hücreler Tarafından Alınım Yolları Ve Hedef Hücrelerdeki Karsinojenez Mekanizmasına Etkisi
The Scientific and Technological Research Council of Turkey (TUBITAK) - RD : TCA Döngüsü ve Glikoliz Yolağındaki Metabolit Seviyelerinin Farklı Aşamalardaki Kolon Kanseri Hücre Hatlarında HPLC Yöntemi ile İncelenmesi
The Scientific and Technological Research Council of Turkey (TUBITAK) - RD : Çoklu İlaç Dirençli Yumurtalık Kanser Tedavisine Yönelik Terapötik Antikor-İlaç Konjugatı Sentezi ve Karakterizasyonu